Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors - eVOLVE-02

Study identifier:D798MC00002

ClinicalTrials.gov identifier:NCT06535607

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase II, Multi-Center study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors

Medical condition

cervical cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

60

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 22 Aug 2024
Estimated Primary Completion Date: 18 Sept 2026
Estimated Study Completion Date: 18 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria